Author Archive: Jeremy Parkinson
The Best 5 Growth Stocks
I like growth, I like momentum and I like positive investor sentiment. I wanted to find all 3 so I took a list of stocks analysts picked as high growth and ran them through Barchart to find the 5 with the most frequent new highs in the last month to get my list. The list […]
More On Germany And Nuclear
This short paper is an upgrading of a document that I published about three years ago. I am resorting to this because of the extreme amount of criticism I received for that contribution, while my present work on the nuclear future is largely overlooked by members of the anti-nuclear booster club. This is almost certainly […]
T2108 Update – Overbought For A Hot Minute With Breakout Charts Galore
(T2108 measures the percentage of stocks trading above their respective 40-day moving averages [DMAs]. It helps to identify extremes in market sentiment that are likely to reverse. To learn more about it, see my T2108 Resource Page. You can follow real-time T2108 commentary on twitter using the #T2108 hashtag. T2108-related trades and other trades are sometimes posted on […]
Overreaching Enthusiasm?
Bullish monetary policy rumblings from China and Europe had kick started a bright opening for markets, but the feel good factor gradually wore off as the day lengthened, and in the end, the day felt oddly bearish. The S&P closed with a bearish inverse hammer on Friday, which could turn into a bearish shooting star […]
Insider Trading Report Edition #231: Notable Buys And Sales
Welcome to edition 231 of Insider Weekends. Insider buying decreased last week with insiders buying $68.12 million of stock compared to $73.83 million in the week prior. Selling increased a little with insiders selling $1.69 billion of stock last week compared to $1.67 billion in the week prior. Sell/Buy Ratio: The insider Sell/Buy ratio is calculated by dividing the total insider […]
OMED Offers Data From Demcizumab; CELG Receives Positive CHMP Opinion For OTEZLA
OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage company developing novel therapeutics which target cancer stem cells (CSCs), or tumor-initiating cells, presented data in two posters highlighting the company’s translational research and biomarker efforts for its tarextumab (anti-Notch2/3, OMP-59R5) and demcizumab (anti-DLL4, OMP-21M18) clinical programs. These data were presented at the 26th EORTC-NCI-AACR Symposium on Molecular […]
Obama’s Amnesty Further Fractures America
President Obama’s decision to ignore the law by granting de facto amnesty to millions of illegal immigrants brought to America as children and those who are parents of children with legal status was a terribly foolish act. It will only serve to exacerbate racial tensions. Polls indicate the overwhelming majority of whites view illegal immigration as threatening. […]
Output Gap Idiocy; Shaky Accounting EU And US Style
Shaky Accounting EU Style Inquiring minds note that Italy Accuses Brussels of ‘Shaky’ Accounting. That’s certainly not a shocking accusation. “Shaky” is exactly what one should expect when you get a bunch of nannycrats who believe Nirvana is on the horizon if wealth and taxes could be redistributed properly. The irony in this case is that […]
3 Auto Stocks To Buy For Surging Growth In 2015
The majority of U.S. equities have outperformed auto stocks during this most recent bull market. However, economic conditions are picking up for this industry. 2015 looks to book solid growth in both domestic and foreign car sales which will lead the charge in gains for these three stocks Bret Jensen loves to own. Global auto […]
